Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy

Original Article

M. Greenhawt, S.B. Sindher, J. Wang, M. O’Sullivan, G.d. Toit, E.H. Kim, D. Albright, S. Anvari, N. Arends, P.D. Arkwright, P. Bégin, K. Blumchen, T. Bourrier, T. Brown-Whitehorn, H. Cassell, E.S. Chan, C.E. Ciaccio, A. Deschildre, A. Divaret-Chauveau, S.L. Dorris, M.J. Dorsey, T. Eiwegger, M. Erlewyn-Lajeunesse, D.M. Fleischer, L.S. Ford, M. Garcia-Lloret, L. Giovannini-Chami, J.O. Hourihane, N. Jay, S.M. Jones, L.A. Kerns, K.M. Kloepfer, S. Leonard, G. Lezmi, J.A. Lieberman, J. Lomas, M. Makhija, C. Parrish, J. Peake, K.P. Perrett, D. Petroni, W. Pfützner, J.A. Pongracic, P. Quinn, R.G. Robison, G. Sanders, L. Schneider, H.P. Sharma, J. Trujillo, P.J. Turner, K. Tuttle, J.E. Upton, P. Varshney, B.P. Vickery, C. Vogelberg, B. Wainstein, R.A. Wood, K.J. Bee, D.E. Campbell, T.D. Green, R. Rouissi, A. Peillon, H.T. Bahnson, T. Bois, H.A. Sampson, and A.W. Burks

N Engl J Med 2023;388:1755-1766

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Course opens: 
05/10/2023
Course expires: 
05/11/2025

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation